April 9, 2018 / 10:56 AM / 7 months ago

BRIEF-Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct Of Tumor Cells

April 9 (Reuters) - Merck & Co Inc:

* KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS

* SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT

* PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below